Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

NCT03751176 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: Panitumumab
DRUG: Irinotecan
DRUG: Folinic acid
DRUG: 5-FU

Sponsor

Grupo Espanol Multidisciplinario del Cancer Digestivo

Collaborators

[object Object]
[object Object]